Prescription medicine
Hydroxyurea Brand names: Droxia, Hydrea, Siklos, Xromi
Hydroxyurea (Hydrea) is a prescription medicine with an FDA approval on record since 1967. FDA's NDC Directory lists it from 10 generic labelers, and pharmacies paid $0.184 per hydroxyurea 500 mg capsule in the October 7, 2026 NADAC survey; its other strengths are brand-only, $4.97 per mL (Xromi 100 mg/mL solution).
- Generic listed
Check it at the source: the hydroxyurea FDA label on DailyMed (effective September 15, 2025, Waylis Therapeutics LLC); the NDA 16295 record on Drugs@FDA; every hydroxyurea label on DailyMed.
Highlights of the record
FDA label of September 15, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageHYDREA is indicated for the treatment of: Resistant chronic myeloid leukemia.
Forms and strengths
- 100 mg
- 200 mg
- 300 mg
- 400 mg
- 500 mg
- 1000 mg
- 100 mg/ml
Capsule; film-coated tablet; solution.
On the market
- Earliest approval on file
- December 7, 1967 Droxia, Waylis Therap; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 7 first August 18, 1995; 4 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 14 of which 10 under generic applications, 4 under brand applications, repackagers included
- Last listed patent
- December 23, 2041 Xromi oral solution; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.184 per capsule Hydroxyurea 500 mg capsule
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 0 since 2015 0 Class I among all firms' recalls; 1 more by firms not listed as its makers
- FAERS reports
- 21,023 through July 30, 2026
What is hydroxyurea used for?
From the label: indications and usageHYDREA is indicated for the treatment of: Resistant chronic myeloid leukemia. Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. HYDREA is an antimetabolite indicated for the treatment of: Resistant chronic myeloid leukemia. ( 1 ) Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation.
Conditions named in the indications of hydroxyurea's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Antimetabolite.
Source: FDA drug label (HYDREA), Waylis Therapeutics LLC, effective September 15, 2025 (SPL set 8d41152f-a98a-4abc-afdf-a909012434a0), via openFDA; the full label on DailyMed
What does the patient leaflet for hydroxyurea say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about DROXIA?DROXIA can cause serious side effects including: Low blood counts are common with DROXIA, including low red blood cells, white blood cells, and platelets, and can be severe and life-threatening. If your white blood cell count becomes very low, you are at increased risk for infection. Your healthcare provider will check your blood cell counts before and during treatment with DROXIA. Your healthcare provider may change your dose or tell you to stop taking DROXIA if you have low blood cell counts. Tell your healthcare provider right away if you get any of the following symptoms: fever chills body aches feeling very tired shortness of breath bleeding or unexplained bruising Cancer. Some people have developed cancer, such as leukemia and skin cancer, after taking DROXIA for a long time. Your healthcare provider will check you for cancer. You should protect your skin from the sun using sunblock, hats, and sun-protective clothing. DROXIA can harm your unborn baby. For females taking DROXIA who can become pregnant: You should talk with your healthcare provider about the risks of DROXIA to your unborn baby. You should use effective birth control during treatment with DROXIA and for at least 6 months after treatment. Your healthcare provider will perform a pregnancy test before you start treatment with DROXIA. You should avoid becoming pregnant during treatment with DROXIA. Tell your healthcare provider right away if you become pregnant or think you may be pregnant. For males taking DROXIA: DROXIA can affect your sperm. If you have a female sexual partner who can become pregnant, you should use a condom during treatment with DROXIA and for at least 1 year after treatment. DROXIA may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you. […]
From the patient leaflet: How should I store DROXIA?Store DROXIA at room temperature between 68°F to 77°F (20°C to 25°C). Keep the DROXIA bottle tightly closed. Call your healthcare provider for instructions on how to throw away (dispose of) DROXIA that is out of date. Keep DROXIA and all medicines out of the reach of children. Keep DROXIA away from pets.
Source: FDA drug label (DROXIA), Waylis Therapeutics LLC, effective September 12, 2025 (SPL set 4ad13dc6-a2ab-4308-96b3-7c642c92cc23), via openFDA; the full label on DailyMed
Is there a generic for hydroxyurea (Hydrea)?
The FDA approved the first generic hydroxyurea on August 18, 1995. 7 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists hydroxyurea from 10 labelers under a generic (ANDA) application and from 4 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists no patent for Hydrea capsules; a patent listed only for Xromi oral solution runs to December 23, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1967 earliest approval on file
- 1995 first generic approved
- 2041 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for hydroxyurea (Hydrea)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.184 per Hydroxyurea 500 mg capsule, down 8% from $0.199 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Hydroxyurea 500 mg capsule (generic)
- Xromi 100 mg/mL solution (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Hydroxyurea 500 mg capsule | Generic | $0.184 per capsule | $5.51 | -8% |
| Siklos 1,000 mg tablet | Brand | $62.00 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $1,859.88 | +3% |
| Siklos 100 mg tablet | Brand | $6.23 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $186.95 | +3% |
| Xromi 100 mg/mL solution | Brand | $4.97 per mL | n/a | +1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has hydroxyurea been recalled?
The FDA's Enforcement Report lists 1 recall naming hydroxyurea since 2015: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of hydroxyurea and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| February 12, 2015 | Class II | Health Innovations Pharmacy, Inc not a listed maker | Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the hydroxyurea label say about other medicines?
The hydroxyurea label names no other medicine on this site. The labels of 16 other medicines name hydroxyurea. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Other labels that name hydroxyurea
Source: FDA drug label (HYDREA), Waylis Therapeutics LLC, effective September 15, 2025 (SPL set 8d41152f-a98a-4abc-afdf-a909012434a0), via openFDA; the full label on DailyMed
What do FAERS reports show for hydroxyurea?
The FDA Adverse Event Reporting System holds 21,023 reports that list hydroxyurea among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3,145 are coded as a death and 7,991 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as hydroxyurea?
37 other medicines are given the same way (oral) and in the same FDA class as hydroxyurea or labeled mainly for the same use (leukemia, lymphoma and myeloma), the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Thioguanine | Leukemia, lymphoma and myeloma | none listed | n/a | No current entry |
| Lenalidomide | Leukemia, lymphoma and myeloma | 18 labelers | n/a | No current entry |
| Dasatinib | Leukemia, lymphoma and myeloma | 14 labelers | $26.46 per tablet 100 mg tablet | No current entry |
| Pomalidomide | Leukemia, lymphoma and myeloma | 11 labelers | n/a | No current entry |
| Imatinib | Leukemia, lymphoma and myeloma | 20 labelers | $0.624 per tablet 100 mg tablet | No current entry |
| Arsenic trioxide | Leukemia, lymphoma and myeloma | none listed | n/a | A presentation being discontinued |
| Nilotinib | Leukemia, lymphoma and myeloma | 6 labelers | n/a | No current entry |
| Cyclophosphamide | Leukemia, lymphoma and myeloma | 4 labelers | $1.67 per capsule 50 mg capsule | No current entry |
Every medicine labeled for the same conditions as hydroxyurea
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to hydroxyurea
- 37 medicines for the same use
- Other antimetabolites
- the pharmacologic class, with prices and generics
- Hydroxyurea side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other